Journal of Pharmacobio-Dynamics
Online ISSN : 1881-1353
Print ISSN : 0386-846X
ISSN-L : 0386-846X
Effects of Long-Term Administration of (4S)-1-Methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl) amino] propionyl}-2-oxoimidazolidine-4-carboxylic Acid Hydrochloride (TA-6366), a New Angiotensin I Converting Enzyme (ACE) Inhibitor,
from the Pre-hypertensive Stage on Morphological Change and Mechanical Property Related to Sodium Ion Permeability in Aorta of Spontaneously Hypertensive Rats (SHRs)
Masami KUBOKinji KOBAYASHIRyuichi ISHIDA
Author information
JOURNAL FREE ACCESS

1992 Volume 15 Issue 11 Pages 657-665

Details
Abstract

Effects of (4S)-1-methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl) amino] propionyl}-2-oxoimidazolidine-4-carboxylic acid hydrochloride (TA-6366) on morphological change and mechanical property related to sodium ion permeability in the aorta of spontaneously hypertensive rats (SHRs) were examined, as compared with those of enalapril and captopril. Ten-week oral administration of TA-6366 (1 and 5 mg/kg/d) from 4 weeks of age impeded aortic media-thickening together with a rise in blood pressure in SHRs. Concomitantly, aorta weights in both groups were markedly decreased. The higher dose of TA-6366 almost fully suppressed the accelerated tension development induced by K+-free medium and decreased total sodium ion content in the aorta. These vascular effects of TA-6366 was more prominent than those of enalapril and captopril at 5 mg/kg/d. The difference in potencies on the above vascular parameters between TA-6366 and these drugs seemed to be mainly related to the difference in their antihypertensive activities. These results suggest that TA-6366 has preventive effects against progression of vascular diseases, particularly atherosclerosis, accompanied with hypertension.

Content from these authors
© The Pharmaceutical Society of Japan
Previous article
feedback
Top